FIBROGEN INC - COMMON

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

02 Apr 2024 17:46:47 By Nasdaq GlobeNewswire

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

26 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

11 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

26 Feb 2024 16:06:00 By Nasdaq GlobeNewswire

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

26 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

20 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

05 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

25 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

09 Dec 2023 17:02:00 By Nasdaq GlobeNewswire

FibroGen Reports Third Quarter 2023 Financial Results

06 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

FibroGen to Report Third Quarter 2023 Financial Results

23 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy

29 Aug 2023 16:15:00 By Nasdaq GlobeNewswire

FibroGen Reports Second Quarter 2023 Financial Results

07 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis

26 Jun 2023 07:04:00 By Nasdaq GlobeNewswire

FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

07 Jun 2023 06:55:00 By Nasdaq GlobeNewswire

FibroGen to Present at Jefferies Global Healthcare Conference

06 Jun 2023 16:01:00 By Nasdaq GlobeNewswire

FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

18 May 2023 07:30:00 By Nasdaq GlobeNewswire

FibroGen Reports First Quarter 2023 Financial Results

08 May 2023 16:01:00 By Nasdaq GlobeNewswire

FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics

08 May 2023 16:00:00 By Nasdaq GlobeNewswire

FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)

05 May 2023 07:30:00 By Nasdaq GlobeNewswire